Working… Menu

The Effect of Green Tea Extract on Type 2 Diabetes With Hyperlipidemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01360567
Recruitment Status : Completed
First Posted : May 25, 2011
Last Update Posted : April 30, 2013
National Yang Ming University
Information provided by (Responsible Party):
Chung-Hua Hsu, Taipei City Hospital

Brief Summary:
The aim of the study is to examine whether the extract of green tea is effective on type 2 diabetes and hyperlipidemia.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Hyperlipidemia Dietary Supplement: Green tea extract Dietary Supplement: Placebo Phase 3

Detailed Description:
Percent change Homa insulin resistance, cholesterol and triglycerol.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 102 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Taipei City Hospital, Taipei, Taiwan
Study Start Date : May 2011
Actual Primary Completion Date : November 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: B formula
Dietary Supplement: Placebo
500 mg . one capsule of placebo, 3 times per day

Experimental: A formula
Green tea extract
Dietary Supplement: Green tea extract
500 mg . one capsule of green tea extract, 3 times per day
Other Name: EGCG: Green tea extract

Primary Outcome Measures :
  1. Percent change of HOMA insulin resistance and TG [ Time Frame: 16 weeks ]

Secondary Outcome Measures :
  1. Percent change of HbA1C and Cholesterol [ Time Frame: 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 20--69 years old
  • Type 2 diabetes for > one year
  • TG >= 150 mg/dl or LDL >= 100 mg/dl

Exclusion Criteria:

  • GPT > 80 mg/dl
  • Creatinine > 1.8 mg/dl
  • Pregnancy
  • AMI
  • Stroke
  • Operational or any not suitable patients diagnosis physician in charge

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01360567

Layout table for location information
Chung-Hua Hsu
Taipei, Taiwan, 886
Taipei City Hospital
Taipei, Taiwan, 886
Sponsors and Collaborators
Taipei City Hospital
National Yang Ming University
Layout table for investigator information
Principal Investigator: Chung-Hua Hsu, MD, PhD Taipei City Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Chung-Hua Hsu, chief medical officer, Taipei City Hospital Identifier: NCT01360567    
Other Study ID Numbers: 100002-63-020
TCH-971103 ( Other Grant/Funding Number: CCMP100-RD-014 )
TCHIRB-971103 ( Other Grant/Funding Number: CCMP100-RD-014 )
First Posted: May 25, 2011    Key Record Dates
Last Update Posted: April 30, 2013
Last Verified: April 2013
Keywords provided by Chung-Hua Hsu, Taipei City Hospital:
green tea
type 2 diabetes
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Lipid Metabolism Disorders